Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD
March 25th 2024The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]
Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD
March 24th 2024The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]
Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA
March 22nd 2024The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh
March 21st 2024The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]
Flaws in Assessment Scales for Neuromuscular Conditions: Laurent Servais, MD, PhD
March 20th 2024The professor of pediatric neuromuscular diseases at the University of Oxford provided commentary on the commonly used scales to assess neuromuscular function and where inconsistencies have been observed. [WATCH TIME: 7 minutes]
The Persistent Burden of Migraine Despite Treatment Advances: Amaal Starling, MD, FAHS, FAAN
March 20th 2024The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about the significant disease burden experienced by patients with migraine even as therapeutics have advanced for the condition. [WATCH TIME: 8 minutes]
Association Between Obesity and Disease Progression in Multiple Sclerosis: Lars Alfredsson, PhD
March 19th 2024The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]
Improving MS Care Through Innovative Trial Designs: Daniel Ontaneda, MD, PhD
March 18th 2024Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]
Consistent Real-World Efficacy of Ofatumumab Therapy for Multiple Sclerosis: Jason Freeman, MD, MBA
March 15th 2024The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Overviewing Cutting-Edge Research at 2024 ACTRIMS Forum: Daniel Ontaneda, MD, PhD
March 14th 2024The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine discussed several notable presentations and topics from the 2024 ACTRIMS Forum, highlighting advances in MS care. [WATCH TIME: 9 minutes]
Raising Awareness for the Lasting Effects of Traumatic Brain Injury: Shae Datta, MD
March 12th 2024The neurologist and migraine expert at NYU Langone Health provided perspective on TBI Awareness Month and the importance of accurate detection and swift care for trauamatic brain injury. [WATCH TIME: 4 minutes]
Adding to the Literature of KIF5A in ALS Pathogensis: Devesh Pant, PhD
March 11th 2024The instructor in the department of cell biology at Emory University provided context on a presentation at MDA 2024 regarding mutations in Kif5a in familial forms of amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
Impact of Indole 3-Lactate Supplementation in Multiple Sclerosis Animal Models: Larissa Jank, MD
March 10th 2024The postdoctoral researcher in the department of neurology at Johns Hopkins School of Medicine discussed findings from a study on the impact of indole 3-lactate supplementation in animal models of multiple sclerosis. [WATCH TIME: 4 minutes]
Addressing Diversity Gaps in Neuromyelitis Optica Spectrum Disorder Research: Mirla Avila, MD
March 8th 2024The director of the Comprehensive Care MS Center at Texas Tech University Health Sciences Center talked about findings from a subgroup analysis of Hispanic or Latin patients from the N-MOmentum trial presented at ACTRIMS Forum 2024. [WATCH TIME: 3 minutes]
Real-World Effectiveness and Safety of Monoclonal Antibodies in NMOSD: Amy Kunchok, MD, PhD
March 7th 2024The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]